Loading...
Publication
Impacto Cardiovascular da Terapia Hormonal de Afirmação de Género
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| Documento em Acesso Embargado até dia 28-02-2028. Tente solicitar cópia ao autor carregando no ficheiro | 633.71 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Introdução: A disforia de género refere-se ao desconforto ou angústia que uma pessoa pode sentir em relação ao seu género biológico, que não corresponde à identidade de género sentida. Por sua vez, estas procuram aproximar a sua aparência àquela que mais lhes traz conforto, recorrendo, muitas vezes, ao uso de hormonas de afirmação de género. Com a presente acessibilidade a estas terapias, surge o desafio de avaliar se existe um impacto real na saúde destes indivíduos provocado pela sua utilização. Objetivo: Avaliar se a terapia hormonal de afirmação de género pode impactar o risco cardiovascular da população transgénero. Métodos: Foi realizada pesquisa de artigos científicos a partir das plataformas Pubmed e Scopus, com recurso às seguintes palavras-chave: "transgender", "gender-affirming hormone therapy", "myocardial infarction", "hypertension" e "venous tromboembolism". Resultados: Foram selecionados 11 estudos aos quais foi adicionado posteriormente outro artigo, encontrado a partir da leitura de outros. Sete artigos tiveram como população em estudo tanto homens como mulheres transgénero, enquanto cinco artigos analisaram apenas homens transgénero. Discussão: Nas mulheres trans, a terapia hormonal parece favorecer o perfil lipídico, aumentando o risco de tromboembolismo por alterações no perfil de coagulação. Já nos homens trans, as alterações no perfil lípido e hematócrito são desfavoráveis, sem alterações relevantes na tensão arterial. Conclusão: Apesar dos artigos apresentaram alguns resultados que parecem influenciar o risco cardiovascular nos transgéneros, estes são contraditórios. Assim, mais estudos são necessários de modo a auferir, com certeza, se a terapia hormonal pode ser um fator de agravamento do risco cardiovascular nesta população.
Introduction: Gender dysphoria refers to the discomfort or distress a person may feel regarding their biological gender, which doesn’t correspond to their felt gender identity. In turn, they seek to bring their appearance closer to that which brings them more comfort, often resorting to the use of gender-affirming hormones. Given the current accessibility to these therapies, the challenge arises of assessing whether there is a real impact on the health of these individuals caused by the use of these hormones. Objective: To evaluate whether gender-affirming hormone therapy can impact the cardiovascular risk of the transgender population. Methods: A search for scientific article was carried out using the Pubmed and Scopus platforms, using the following keywords: “Transgender”, “Gender-affirming Hormone therapy”, “Myocardial Infarction”, “Hypertension” and “Venous Thromboembolism” Results: 11 studies were selected, to which another article was later added, found through the analysis of the others. Seven articles had both transgender men and women as their study population, while five articles analyzed only transgender men. Discussion: In trans women, hormonal therapy appears to improve the lipid profile, however, the risk of thromboembolism is increased by changes in coagulation profile. In trans men, changes in lipid profiles and hematocrit are unfavorable, without relevant changes in blood pressure. Conclusion: Although these articles present findings that suggest potential cardiovascular risk in transgender individuals, the results are contradictory. Therefore, further research is needed to determine with certainty whether hormone therapy contributes to an increased cardiovascular risk in this population.
Introduction: Gender dysphoria refers to the discomfort or distress a person may feel regarding their biological gender, which doesn’t correspond to their felt gender identity. In turn, they seek to bring their appearance closer to that which brings them more comfort, often resorting to the use of gender-affirming hormones. Given the current accessibility to these therapies, the challenge arises of assessing whether there is a real impact on the health of these individuals caused by the use of these hormones. Objective: To evaluate whether gender-affirming hormone therapy can impact the cardiovascular risk of the transgender population. Methods: A search for scientific article was carried out using the Pubmed and Scopus platforms, using the following keywords: “Transgender”, “Gender-affirming Hormone therapy”, “Myocardial Infarction”, “Hypertension” and “Venous Thromboembolism” Results: 11 studies were selected, to which another article was later added, found through the analysis of the others. Seven articles had both transgender men and women as their study population, while five articles analyzed only transgender men. Discussion: In trans women, hormonal therapy appears to improve the lipid profile, however, the risk of thromboembolism is increased by changes in coagulation profile. In trans men, changes in lipid profiles and hematocrit are unfavorable, without relevant changes in blood pressure. Conclusion: Although these articles present findings that suggest potential cardiovascular risk in transgender individuals, the results are contradictory. Therefore, further research is needed to determine with certainty whether hormone therapy contributes to an increased cardiovascular risk in this population.
Description
Keywords
Transgénero Terapia Hormonal de Afirmação de Género Enfarte Agudo do Miocárdio Hipertensão Tromboembolismo Venoso Transgender Gender-Affirming Hormone Therapy Myocardial Infarction Hypertension Venous Tromboembolism